TriLink BioTechnologies and Nacalai USA enter into distribution agreement

TriLink BioTechnologies (TriLink), has entered into an agreement with Nacalai USA, Inc., a San Diego based manufacturing and marketing company, for the distribution of TriLink's modified nucleic acid products in Japan, Singapore, South Korea and Taiwan.

"With TriLink's unique high quality product offering and Nacalai's key role as a bridge to bringing new technologies to the Japanese research market, we feel that we can now have yet another opportunity to advance science. We are excited to join forces with the great team at Nacalai USA," stated TriLink CEO, Richard Hogrefe, Ph.D.

"We are excited about the opportunity to introduce TriLink's cutting-edge technology to the Japanese scientific research community. We believe TriLink's unique CleanAmp™ products will bring us a new business in the Japanese market," commented Toshi Ono, VP and COO at Nacalai USA.

The agreement will provide researchers in the Asian market access to high quality, modified nucleic acid products to further advance research efforts in areas such as molecular biology and proteomics.